Menin Inhibitors
2 drugsAbout Menin
Menin, encoded by the *MEN1* gene, is a protein target in oncology. Its precise mechanisms of action are still being investigated, but its importance in cancer biology is increasingly recognized.
While there is currently no genetic evidence data available linking *MEN1* mutations to specific diseases, the approval of Menin-targeting drugs underscores its therapeutic potential in oncology.
Menin is targeted by two FDA-approved small molecule drugs, REVUFORJ (SYNDAX) and KOMZIFTI (KURA), both indicated for oncology. REVUFORJ was the first approved in 2024, followed by KOMZIFTI in 2025.
Strategic Insights
ℹ️ How we calculate- Validated target with strong trial activity and 85% attractiveness score.
- White space opportunity in Acute Myeloid Leukemia With KMT2A Rearrangement with only 2 trials.
Top Drugs
The competitive landscape consists of SYNDAX and KURA, each with an approved Menin-targeting drug.
The presence of only two companies suggests a relatively open market with potential for new entrants.
Drug Modality Landscape
Modalities
Routes of Administration
Menin is amenable to small molecule drugs, with oral options available for convenient dosing.
Exploring alternative modalities like PROTACs or antibodies could provide a competitive advantage.
Clinical Trials 51 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 37 | 10 | 0 | 27 | 100% |
| Phase 2 | 5 | 1 | 0 | 4 | 100% |
| Phase 3 | 6 | 2 | 0 | 4 | 100% |
| Phase 4 | 3 | 2 | 1 | 0 | 67% |
Top Sponsors
By Modality
Top Conditions
Drug Approval Timeline (2024 - 2025)
The first Menin-targeting drug was approved in 2024, with the most recent approval in 2025.
The recent approvals suggest growing interest and investment in Menin as a therapeutic target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 43 clinical trials targeting Menin.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities